PREDICTORS OF CARDIAC EVENTS AND ADVERSE CLINICAL OUTCOMES IN PATIENTS WITH CHF FC I-IV SEVERITY AND CONCOMITANT DIABETES WITHIN 12 MONTHS OF OBSERVATION
Abstract
Novel biochemical markers of chronic heart failure can serve as a useful tool for the early diagnosis of the disease, for monitoring the effectiveness of pharmacotherapy (personalized medicine), and for prognosis its clinical outcomes. They can play an important role in the risk stratification of patients. According to he data of epidemiological studies of diabetes mellitus patients constituted 28.0% of surveyed with CHF. More 90.0% of cases of them were in FC III-IV heart failure severity. The unfavorable current of disease was observed in 73.0% of diabetes patients. Galectin-3 plays important role in the evaluation of heart failure progression. Clinical trials proved that Galectin-3 is a valuable marker of outcome prognosis in patients with CHF with concomitant diabetes mellitus.
About the Author
E. K. Kurlianskaya
ГУ "Республиканский научно-практический центр "Кардиология"
Russian Federation
Russian Federation
References
1. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study / G.M. Felker Circ Heart Fail. - 2012. - Vol. 5 (1). - P. 72-78.
2. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study / D.J. Lok [et al.] // Clin Res Cardiol. - 2010. - Vol. 99 (5). - P. 323-328.
3. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT / I.S. Anand [et al.] // Eur J Heart Fail. - 2013. - Vol. 15 (5). - P. 511-518.
4. Braunwald, E. Biomarkers in Heart Failure / E. Braunwald // N Engl J Med. - 2008. - Vol. 358. - P. 2148-2159.
5. Kramer, F. Galectin-3: clinical utility and prognostic value in patients with heart failure / F. Kramer // Reasearch Reports in Clinical Cardiology. - 2013. - Vol. 4. - P. 13-12.
6. Expression and immunohistochemical localization of galectin-3 in various mouse tissues / H. Kim [et al.] // Cell Biol Int. - 2007. - Vol. 31 (7). - P. 655-662.
7. Galectin-3 expression in human atherosclerotic lesions / M. Nachtigal [et al.] // Am J Pathol 1998;152:1199-1208.
8. Nachtigal, M. Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in apoEdeficient mice / M. Nachtigal, A. Ghaffar, E.P. Mayer // Am J Pathol. - 2008. - Vol. 172. - P. 247-255.
9. Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice / G. Pugliese [et al.] // FASEB J. - 2001. - Vol. 15. - P. 2471-2479.
Review
For citations:
Kurlianskaya E.K. PREDICTORS OF CARDIAC EVENTS AND ADVERSE CLINICAL OUTCOMES IN PATIENTS WITH CHF FC I-IV SEVERITY AND CONCOMITANT DIABETES WITHIN 12 MONTHS OF OBSERVATION. Medical and Biological Problems of Life Activity. 2016;(1):204-208. (In Russ.)
Views: 86
Email this article 